Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Farmers Insurance
McKinsey
Teva
Citi
Healthtrust
Harvard Business School
QuintilesIMS
Moodys

Generated: July 16, 2018

DrugPatentWatch Database Preview

ALECENSA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Alecensa, and when can generic versions of Alecensa launch?

Alecensa is a drug marketed by Hoffmann-la Roche and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-five patent family members in thirty-six countries.

The generic ingredient in ALECENSA is alectinib hydrochloride. One supplier is listed for this compound. Additional details are available on the alectinib hydrochloride profile page.
Summary for ALECENSA
International Patents:65
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 89
Clinical Trials: 5
Patent Applications: 34
DailyMed Link:ALECENSA at DailyMed
Drug patent expirations by year for ALECENSA
Generic Entry Opportunity Date for ALECENSA
Generic Entry Date for ALECENSA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ALECENSA
Drug ClassKinase Inhibitor
Mechanism of ActionKinase Inhibitors
Synonyms for ALECENSA
1256589-74-8
3341AH
5H-Benzo[B]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-ipperidinyl]-11-oxo-, hydrochloride (1:1)
9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile hydrochloride (1:1)
9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile monohydrochloride salt
9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride
ACN-050755
AF-802 hydrochloride
AGN-PC-09O9BF
AK174941
AKOS025404940
Alecensa (TN)
Alectinib Hydrochloride
Alectinib hydrochloride (JAN)
Alectinib Hydrochloride;AF-802 Hydrochloride;CH-5424802 Hydrochloride;RG-7853 Hydrochloride;RO-5424802 Hydrochloride
alectinib monohydrochloride
AOB87772
AS-17062
C30H34N4O2.ClH
CH 5424802, Alectinib HCl
CH5424802 (Hydrochloride)
CH5424802 HCl
CH5424802 HCl (AF 802 HCl, Alectinib HCl)
CH5424802 HCl salt, Alectinib HCl salt, AF802 HCl salt
CH5424802 Hydrochloride
CH5424802(Hydrochloride)
CHEBI:62268
CHEMBL3707320
CS-3480
D10450
DTXSID10154841
EX-A1553
GYABBVHSRIHYJR-UHFFFAOYSA-N
HY-13011A
KS-00001D3B
MFCD27987893
MolPort-039-137-749
P9YY73LO6J
SCHEMBL14991271
UNII-P9YY73LO6J

US Patents and Regulatory Information for ALECENSA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for ALECENSA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00024 Denmark ➤ Try a Free Trial PRODUCT NAME: ALECTINIB, ELLER SALT ELLER SOLVAT DERAF, HERUNDER I FORM AF HYDROCHLORID; REG. NO/DATE: EU/1/16/1169/01 20170220
90024-2 Sweden ➤ Try a Free Trial PRODUCT NAME: ALECTINIB OR SALT OR SOLVATE THEREOF; REG. NO/DATE: EU/1/16/1169/001 20170220
0876 Netherlands ➤ Try a Free Trial PRODUCT NAME: ALECTINIB DAN WEL EEN ZOUT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1169/001 20170220
2017017 Lithuania ➤ Try a Free Trial PRODUCT NAME: ALEKTINIBAS ARBA JO DRUSKA, ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/16/1169 20170216
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Merck
Julphar
Fuji
Cantor Fitzgerald
Express Scripts
UBS
Fish and Richardson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.